B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...

Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

Shares of FHTX opened at $4.19 on Wednesday. Foghorn Therapeutics has a one year low of $2.70 and a one year high of $10.25. The firm has a market capitalization of $233.01 million, a P/E ratio of ...

Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports.

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq ... at the AACR Annual Meeting in April, with partner Lilly,” said Adrian Gottschalk, President and Chief Executive ...

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...